As the holiday season approaches, pediatricians remind parents to prioritize children's health alongside holiday shopping.

Researchers have identified new roles for a protein long known to protect against severe flu infection -- among them, raising the minimum number of viral particles needed to cause sickness.

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated ...

Vaxart ( (VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a ...

Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...

The cooler weather and holidays are fast approaching, along with the deadlines to get vaccinated if you want the most protection from respiratory viruses. "We're currently just on the brink of ...

The adverse event in the earlier clinical trial involved amyotrophic lateral sclerosis, which wasn't related to vaccination.

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...